Boston Common Asset Management LLC Has $18.20 Million Stake in Colgate-Palmolive (NYSE:CL)

Boston Common Asset Management LLC lowered its stake in shares of Colgate-Palmolive (NYSE:CL) by 0.4% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 175,327 shares of the company’s stock after selling 635 shares during the period. Boston Common Asset Management LLC’s holdings in Colgate-Palmolive were worth $18,201,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. UMB Bank n.a. increased its stake in Colgate-Palmolive by 9.1% in the third quarter. UMB Bank n.a. now owns 17,793 shares of the company’s stock valued at $1,847,000 after acquiring an additional 1,487 shares during the period. Cadinha & Co. LLC lifted its stake in Colgate-Palmolive by 10.8% during the third quarter. Cadinha & Co. LLC now owns 4,100 shares of the company’s stock worth $426,000 after purchasing an additional 400 shares during the period. BSN CAPITAL PARTNERS Ltd acquired a new stake in Colgate-Palmolive during the third quarter valued at approximately $4,500,000. Wedmont Private Capital grew its stake in shares of Colgate-Palmolive by 16.6% in the 3rd quarter. Wedmont Private Capital now owns 8,096 shares of the company’s stock valued at $798,000 after purchasing an additional 1,153 shares during the period. Finally, Hexagon Capital Partners LLC raised its holdings in shares of Colgate-Palmolive by 9.8% in the 3rd quarter. Hexagon Capital Partners LLC now owns 1,399 shares of the company’s stock worth $145,000 after buying an additional 125 shares in the last quarter. Institutional investors and hedge funds own 80.41% of the company’s stock.

Insider Transactions at Colgate-Palmolive

In related news, Director Martina Hundmejean sold 2,313 shares of Colgate-Palmolive stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $103.86, for a total transaction of $240,228.18. Following the transaction, the director now owns 11,755 shares of the company’s stock, valued at $1,220,874.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Colgate-Palmolive news, EVP Gregory Malcolm sold 10,533 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $103.10, for a total value of $1,085,952.30. Following the completion of the transaction, the executive vice president now directly owns 10,377 shares of the company’s stock, valued at approximately $1,069,868.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Martina Hundmejean sold 2,313 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $103.86, for a total value of $240,228.18. Following the sale, the director now directly owns 11,755 shares in the company, valued at approximately $1,220,874.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,490 shares of company stock worth $4,486,063. 0.34% of the stock is currently owned by company insiders.

Colgate-Palmolive Trading Down 1.7 %

CL opened at $99.24 on Friday. The firm has a 50 day simple moving average of $103.65 and a 200 day simple moving average of $97.05. Colgate-Palmolive has a fifty-two week low of $68.54 and a fifty-two week high of $109.30. The company has a market cap of $81.09 billion, a price-to-earnings ratio of 28.77, a price-to-earnings-growth ratio of 3.54 and a beta of 0.40. The company has a debt-to-equity ratio of 16.90, a current ratio of 1.06 and a quick ratio of 0.70.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Friday, July 26th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.04. Colgate-Palmolive had a return on equity of 470.19% and a net margin of 14.21%. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $5 billion. During the same quarter in the prior year, the business posted $0.77 EPS. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. On average, sell-side analysts anticipate that Colgate-Palmolive will post 3.57 earnings per share for the current year.

Colgate-Palmolive Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Friday, October 18th will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 18th. This represents a $2.00 annualized dividend and a dividend yield of 2.02%. Colgate-Palmolive’s payout ratio is currently 57.97%.

Analysts Set New Price Targets

CL has been the topic of several recent analyst reports. Stifel Nicolaus boosted their target price on shares of Colgate-Palmolive from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. BNP Paribas started coverage on shares of Colgate-Palmolive in a research report on Monday, June 24th. They issued an “outperform” rating and a $109.00 price target on the stock. Barclays raised their price objective on shares of Colgate-Palmolive from $91.00 to $96.00 and gave the stock an “equal weight” rating in a report on Monday, July 29th. Morgan Stanley boosted their target price on Colgate-Palmolive from $103.00 to $111.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. Finally, Evercore ISI increased their price target on Colgate-Palmolive from $100.00 to $106.00 and gave the stock an “outperform” rating in a research report on Thursday, July 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $104.74.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.